KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBITDA (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of EBITDA readings, the most recent being $201.2 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 1046.8% to $201.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $515.0 million, a 313.68% increase, with the full-year FY2025 number at $328.2 million, up 213.44% from a year prior.
  • EBITDA hit $201.2 million in Q1 2026 for Alnylam Pharmaceuticals, up from $113.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $259.3 million in Q3 2025 to a low of -$407.5 million in Q3 2022.
  • Median EBITDA over the past 5 years was -$93.5 million (2024), compared with a mean of -$79.8 million.
  • Biggest five-year swings in EBITDA: tumbled 166.73% in 2024 and later skyrocketed 1046.8% in 2026.
  • Alnylam Pharmaceuticals' EBITDA stood at -$208.4 million in 2022, then soared by 38.13% to -$128.9 million in 2023, then increased by 27.5% to -$93.5 million in 2024, then surged by 221.15% to $113.2 million in 2025, then skyrocketed by 77.7% to $201.2 million in 2026.
  • The last three reported values for EBITDA were $201.2 million (Q1 2026), $113.2 million (Q4 2025), and $259.3 million (Q3 2025) per Business Quant data.